<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="382">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on March 04, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04603404</url>
  </required_header>
  <id_info>
    <org_study_id>MISSION-HFpEF</org_study_id>
    <nct_id>NCT04603404</nct_id>
  </id_info>
  <brief_title>Multimodality Imaging in the Screening, Diagnosis and Risk StratifictiON of HFpEF</brief_title>
  <official_title>Multimodality Imaging (Cardiovascular Magnetic Resonance Imaging, Echocardiography, and Nuclear Medicine Imaging) in the Screening, Diagnosis and Risk Stratification of Heart Failure With Preserved Ejection Fraction (HFpEF).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese Academy of Medical Sciences, Fuwai Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese Academy of Medical Sciences, Fuwai Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The incidence of Heart failure with preserved ejection fraction (HFpEF) in Heart failure&#xD;
      patients increases rapidly. However, the current clinical awareness is insufficient, and the&#xD;
      cardiac structural and functional injury are not well understood. It is difficult to&#xD;
      recognize the subclinical changes of the cardiac in the early stage with conventional imaging&#xD;
      techniques, and it is common to ignore the existence of the clinical alterations. This study&#xD;
      aimed to investigate the cardiac features, early diagnosis and risk factors of HFpEF&#xD;
      patients, based on the multi-modal (Magnetic resonance imaging- nuclear medicine imaging-&#xD;
      echocardiography) imaging, combined with large data and artificial intelligence. This study&#xD;
      will provide deep insights into the HFpEF derived from different causes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Heart Failure with Preserved Ejection Fraction (HFpEF) is a special subtype of Heart Failure&#xD;
      (HF), and the incidence of HF cases is rising to 4.5 million every year, according to&#xD;
      &quot;Chinese cardiovascular disease report 2018&quot; and &quot;China Heart Failure and diagnostic&#xD;
      guidelines 2018&quot;. In 2000, the incidence of patients with chronic Heart Failure is as high as&#xD;
      0.9%, and faces significant increase with the increase of age. Moreover, HFpEF patients&#xD;
      accounted for over 50% of HF, presenting normal left ventricular ejection fraction (LVEF),&#xD;
      and nonspecific HF clinical performance. In addition, as a heterogenous disease, HFpEF is&#xD;
      often associated with various comorbidities, including hypertension (~ 75%), diabetes (~&#xD;
      40%), obesity (&gt; 80%), aging (~ 75 years), renal dysfunction (25-50%), pulmonary hypertension&#xD;
      (~ 50%), and other diseases. There is still much confusion about the pathophysiology of the&#xD;
      disease, and no effective treatment was confirmed, therefore the diagnosis and treatment of&#xD;
      HFpEF has some challenges. With the increase of cardiovascular risk factors such as&#xD;
      hypertension (morbidity: 23.2% in 2018), diabetes (morbidity:10.9% in 2018, treatment rate&#xD;
      32.2%) and the aging trend, the morbidity and mortality of HFpEF are still on the rise,&#xD;
      posing a threat to the life quality of more and more patients. Early identification and&#xD;
      intervention of HFpEF is an important method to reduce mortality and improve prognosis. Yet,&#xD;
      many studies have explored the role of different biochemical and inflammatory markers in the&#xD;
      diagnosis and prognosis assessment of HFpEF, limited for mixed indicators and low&#xD;
      sensitivity.&#xD;
&#xD;
      Cardiac Magnetic Resonance imaging (CMR) is a non-invasive &quot;one-stop&quot; examination, including&#xD;
      cardiac structure, function, tissue characteristics, blood perfusion examination. In&#xD;
      particular, the emerging T1 mapping and Feature Tracking (FT) techniques enable the early and&#xD;
      quantitive identification of cardiac dysfunction prior to abnormal LVEF. It has been found&#xD;
      that the Extracellular Volume Fraction (ECV) based on T1 mapping and the myocardial strain&#xD;
      parameters based on FT have the ability to diagnose and predict the prognosis of HFpEF&#xD;
      patients. Echocardiography takes advantages in early identification of HFpEF patients and&#xD;
      reveals the diastolic dysfunction. Nuclear medicine imaging shows priorities in blood&#xD;
      perfusion and myocardial viability verification. Magnetic resonance imaging -&#xD;
      echocardiography - nuclear medicine multimodal imaging complements and promotes each other,&#xD;
      for example, molecular nuclear medicine imaging (recognition of metabolism), echocardiography&#xD;
      (primary selection and determination of diastolic dysfunction), as well as the noninvasive&#xD;
      high-resolution magnetic resonance and new emerging molecular imaging (identification of&#xD;
      macroscopic, microscopic structure and function). The multimodel imaging overcomes the limits&#xD;
      of single imaging method, greatly improves the accuracy of early diagnosis ability. However,&#xD;
      large studies are based on small samples, and the comprehensive markers derived from&#xD;
      large-scale study are lacked. Domestic relevant studies are in the initial stage.&#xD;
&#xD;
      To sum up, this study attempts to achieve early diagnosis and intervention of HFpEF and&#xD;
      improve life quality of HFpEF patients through a large-scale study based on multimodel&#xD;
      imaging (CMR imaging, echocardiography, nuclear medicine imaging). This study is expected to&#xD;
      deepen the understanding of the pathogenesis and pathophysiological characteristic of HFpEF,&#xD;
      providing a set of parameters based on multimodel imaging. Hence, assisting in early&#xD;
      identification of cardiac structure and function change, early diagnosis of HFpEF and&#xD;
      achieving risk stratification. In other way, the marker derived from this study may help&#xD;
      target treatment of HFpEF.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2020</start_date>
  <completion_date type="Anticipated">December 2026</completion_date>
  <primary_completion_date type="Anticipated">December 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>All-cause Death</measure>
    <time_frame>1-3 year</time_frame>
    <description>Rate or number of All-cause Death</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cardiovascular Death</measure>
    <time_frame>1-3 year</time_frame>
    <description>Rate or number of Cardiovascular Death</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hospitalization Due to Heart Failure</measure>
    <time_frame>1-3 year</time_frame>
    <description>Rate or number of Hospitalization Due to Heart Failure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Implantable cardioverter-defibrillator Implantation</measure>
    <time_frame>1-3 year</time_frame>
    <description>Rate or number of Implantable cardioverter-defibrillator Implantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart Transplantation Heart Transplantation</measure>
    <time_frame>1-3 year</time_frame>
    <description>Rate or number of Heart Transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pacemaker Implantation</measure>
    <time_frame>1-3 year</time_frame>
    <description>Rate or number of Pacemaker Implantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Atrial fibrillation</measure>
    <time_frame>1-3 year</time_frame>
    <description>Rate or number of Atrial fibrillation</description>
  </secondary_outcome>
  <enrollment type="Anticipated">430</enrollment>
  <condition>Heart Failure, Diastolic</condition>
  <eligibility>
    <study_pop>
      <textblock>
        This study is a prospective study with HFpEF patients, diagnosed based on 2016 and 2019&#xD;
        European Society of Cardiology (ESC) concensus. The inclusion criteria include left&#xD;
        ventricular ejection fraction (LVEF)≥50%；N-terminal pro-b type natriuretic peptide&#xD;
        (NT-proBNP)&gt;220pg/ml or b type natriuretic peptide (BNP) &gt;80 pg/ml; symptoms and syndromes&#xD;
        of heart failure; and at least one criteria of cardiac structure (left ventricular&#xD;
        hypertrophy, or left atrial enlargement) and function abnormalities. We exclude patients&#xD;
        with special cardiomyopathy, ; Infarction, myocardial fibrosis caused by ischemic&#xD;
        cardiomyopathyand acute coronary syndrome; Severe arrhythmia; Severe primary cardiac&#xD;
        valvular disease; Restrictive pericardial disease; Refuse to participate in the study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  left ventricular ejection fraction (LVEF)≥50%；&#xD;
&#xD;
          -  N-terminal pro-b type natriuretic peptide (NT-proBNP)&gt;220pg/ml or b type natriuretic&#xD;
             peptide (BNP) &gt;80 pg/ml;&#xD;
&#xD;
          -  symptoms and syndromes of heart failure;&#xD;
&#xD;
          -  At least one criteria of cardiac structure (left ventricular hypertrophy, or left&#xD;
             atrial enlargement) and function abnormalities (based on tissue doppler, color&#xD;
             doppler).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Special types of cardiomyopathy, including hypertrophic cardiomyopathy, restricted&#xD;
             cardiomyopathy, etc.&#xD;
&#xD;
          -  Infarction, myocardial fibrosis caused by ischemic cardiomyopathy and acute coronary&#xD;
             syndrome ;&#xD;
&#xD;
          -  Severe arrhythmia;&#xD;
&#xD;
          -  Severe primary cardiac valvular disease;&#xD;
&#xD;
          -  Restrictive pericardial disease;&#xD;
&#xD;
          -  Refuse to participate in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Minjie Lu, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fuwai Hospital, National Center for Cardiovascular Diseases.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Minjie Lu, PhD</last_name>
    <phone>86 10 88396941</phone>
    <email>coolkan@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fuwai Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100037</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Minjie Lu, PhD</last_name>
      <phone>+86 10 88398175</phone>
      <email>coolkan@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Campbell RT, McMurray JJ. Comorbidities and differential diagnosis in heart failure with preserved ejection fraction. Heart Fail Clin. 2014 Jul;10(3):481-501. doi: 10.1016/j.hfc.2014.04.009. Review.</citation>
    <PMID>24975911</PMID>
  </results_reference>
  <results_reference>
    <citation>Shah SJ, Kitzman DW, Borlaug BA, van Heerebeek L, Zile MR, Kass DA, Paulus WJ. Phenotype-Specific Treatment of Heart Failure With Preserved Ejection Fraction: A Multiorgan Roadmap. Circulation. 2016 Jul 5;134(1):73-90. doi: 10.1161/CIRCULATIONAHA.116.021884. Review.</citation>
    <PMID>27358439</PMID>
  </results_reference>
  <results_reference>
    <citation>Altara R, Giordano M, Nordén ES, Cataliotti A, Kurdi M, Bajestani SN, Booz GW. Targeting Obesity and Diabetes to Treat Heart Failure with Preserved Ejection Fraction. Front Endocrinol (Lausanne). 2017 Jul 17;8:160. doi: 10.3389/fendo.2017.00160. eCollection 2017. Review.</citation>
    <PMID>28769873</PMID>
  </results_reference>
  <results_reference>
    <citation>De Keulenaer GW, Brutsaert DL. Systolic and diastolic heart failure: different phenotypes of the same disease? Eur J Heart Fail. 2007 Feb;9(2):136-43. Epub 2006 Aug 1. Review.</citation>
    <PMID>16884955</PMID>
  </results_reference>
  <results_reference>
    <citation>Guazzi M. Pulmonary hypertension in heart failure preserved ejection fraction: prevalence, pathophysiology, and clinical perspectives. Circ Heart Fail. 2014 Mar 1;7(2):367-77. doi: 10.1161/CIRCHEARTFAILURE.113.000823. Review.</citation>
    <PMID>24643889</PMID>
  </results_reference>
  <results_reference>
    <citation>Simmonds SJ, Cuijpers I, Heymans S, Jones EAV. Cellular and Molecular Differences between HFpEF and HFrEF: A Step Ahead in an Improved Pathological Understanding. Cells. 2020 Jan 18;9(1). pii: E242. doi: 10.3390/cells9010242. Review.</citation>
    <PMID>31963679</PMID>
  </results_reference>
  <results_reference>
    <citation>Loai S, Cheng HM. Heart failure with preserved ejection fraction: the missing pieces in diagnostic imaging. Heart Fail Rev. 2020 Mar;25(2):305-319. doi: 10.1007/s10741-019-09836-8. Review.</citation>
    <PMID>31364028</PMID>
  </results_reference>
  <results_reference>
    <citation>Marwick TH, Shah SJ, Thomas JD. Myocardial Strain in the Assessment of Patients With Heart Failure: A Review. JAMA Cardiol. 2019 Mar 1;4(3):287-294. doi: 10.1001/jamacardio.2019.0052. Review.</citation>
    <PMID>30810702</PMID>
  </results_reference>
  <results_reference>
    <citation>Su MY, Lin LY, Tseng YH, Chang CC, Wu CK, Lin JL, Tseng WY. CMR-verified diffuse myocardial fibrosis is associated with diastolic dysfunction in HFpEF. JACC Cardiovasc Imaging. 2014 Oct;7(10):991-7. doi: 10.1016/j.jcmg.2014.04.022. Epub 2014 Sep 17.</citation>
    <PMID>25240451</PMID>
  </results_reference>
  <results_reference>
    <citation>Harinstein ME, Soman P. Radionuclide Imaging Applications in Cardiomyopathies and Heart Failure. Curr Cardiol Rep. 2016 Mar;18(3):23. doi: 10.1007/s11886-016-0699-8. Review.</citation>
    <PMID>26841785</PMID>
  </results_reference>
  <results_reference>
    <citation>Recommendations for Cardiac Chamber Quantification by Echocardiography in Adults: An Update from the American Society of Echocardiography and the European Association of, Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2016 Apr;17(4):412. doi: 10.1093/ehjci/jew041. Epub 2016 Mar 15.</citation>
    <PMID>26983884</PMID>
  </results_reference>
  <results_reference>
    <citation>Schnelle M, Catibog N, Zhang M, Nabeebaccus AA, Anderson G, Richards DA, Sawyer G, Zhang X, Toischer K, Hasenfuss G, Monaghan MJ, Shah AM. Echocardiographic evaluation of diastolic function in mouse models of heart disease. J Mol Cell Cardiol. 2018 Jan;114:20-28. doi: 10.1016/j.yjmcc.2017.10.006. Epub 2017 Oct 19.</citation>
    <PMID>29055654</PMID>
  </results_reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>October 14, 2020</study_first_submitted>
  <study_first_submitted_qc>October 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 26, 2020</study_first_posted>
  <last_update_submitted>February 1, 2021</last_update_submitted>
  <last_update_submitted_qc>February 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Medical Sciences, Fuwai Hospital</investigator_affiliation>
    <investigator_full_name>Minjie Lu</investigator_full_name>
    <investigator_title>Vice Director of Magnetic Resonance Imaging</investigator_title>
  </responsible_party>
  <keyword>heart failure with preserved ejection fraction</keyword>
  <keyword>cardiovascular magnetic resonance imaging</keyword>
  <keyword>echocardiography</keyword>
  <keyword>nuclear medicine imaging</keyword>
  <keyword>early diagnosis</keyword>
  <keyword>prognosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Heart Failure, Diastolic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

